WEKO3
アイテム
{"_buckets": {"deposit": "b744a6d9-30e2-4e5e-9266-26d71ca8cfc1"}, "_deposit": {"created_by": 1, "id": "477", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "477"}, "status": "published"}, "_oai": {"id": "oai:showa.repo.nii.ac.jp:00000477", "sets": ["57"]}, "author_link": ["2260", "2261", "2264", "2265", "2266", "2267", "2262", "2263"], "item_10002_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-03", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "9", "bibliographicPageStart": "1", "bibliographicVolumeNumber": "30", "bibliographic_titles": [{"bibliographic_title": "The Showa University journal of medical sciences"}]}]}, "item_10002_description_6": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "We assessed the overall efficacy and safety of a long-acting muscarinic antagonist (LAMA) added to an inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) as a combination therapy (LAMA+ICS/LABA) versus LAMA monotherapy in patients with chronic obstructive pulmonary disease (COPD). The overall efficacy and safety of LAMA+ICS/LABA versus LAMA in patients with COPD were assessed by a meta-analysis of randomized controlled trials (RCTs). We identified LAMA+ICS/LABA RCTs by searching PubMed, Scopus, and the Cochrane Library database. Primary efficacy outcomes were changes in forced expiratory volume in 1 second (FEV1.0) from baseline. Incidences of all adverse events (AAEs) were the primary safety outcomes. Pooled estimates are presented as mean differences (MDs) or risk ratios (RRs) with 95% confidence intervals (CIs). Analyses included intention-to-treat cases. Three LAMA+ICS/LABA RCTs met the criteria for inclusion in this study. The MD, RRs, and their 95% CIs regarding changes in FEV1.0 for LAMA+ICS/LABA compared with those of LAMA were 0.08 (0.04 to 0.13); RRs and 95% CIs for AAEs of LAMA+ICS/LABA compared with those of LAMA were 1.03 (0.82 to 1.29). Conclusions: Pulmonary function was significantly improved in the LAMA+ICS/LABA group with no significant increase in AAE risk. These results provide important analysis regarding the overall efficacy and safety of LAMA+ICS/LABA in patients with COPD.", "subitem_description_type": "Abstract"}]}, "item_10002_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Showa University Society"}]}, "item_10002_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.15369/sujms.30.1", "subitem_relation_type_select": "DOI"}}]}, "item_10002_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AA10781651", "subitem_source_identifier_type": "NCID"}]}, "item_10002_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0915-6380 ", "subitem_source_identifier_type": "ISSN"}]}, "item_10002_text_26": {"attribute_name": "アイテムタイプ", "attribute_value_mlt": [{"subitem_text_value": "学内発行雑誌 / Departmental Bulletin Paper"}]}, "item_10002_text_27": {"attribute_name": "POS_INDEX", "attribute_value_mlt": [{"subitem_text_value": "学内発行雑誌/The Showa University journal of medical sciences/Vol.30(2018)/No.1"}]}, "item_10002_version_type_20": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "ANDO, Koichi"}], "nameIdentifiers": [{"nameIdentifier": "2260", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "TANAKA, Akihiko"}], "nameIdentifiers": [{"nameIdentifier": "2261", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "KUSUMOTO, Sojiro"}], "nameIdentifiers": [{"nameIdentifier": "2262", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "YAMAOKA, Toshimitsu"}], "nameIdentifiers": [{"nameIdentifier": "2263", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OHMORI, Tohru"}], "nameIdentifiers": [{"nameIdentifier": "2264", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "OHNISHI, Tsukasa"}], "nameIdentifiers": [{"nameIdentifier": "2265", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "INOUE, Shin"}], "nameIdentifiers": [{"nameIdentifier": "2266", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "SAGARA, Hironori"}], "nameIdentifiers": [{"nameIdentifier": "2267", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-07-26"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "S30_1.pdf", "filesize": [{"value": "517.7 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 517700.00000000006, "url": {"label": "S30_1.pdf", "url": "https://showa.repo.nii.ac.jp/record/477/files/S30_1.pdf"}, "version_id": "b66ab89f-5695-47eb-a8cb-f119089303ad"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "A Long-acting Muscarinic Antagonist (LAMA) Added to an Inhaled Corticosteroid and Long-acting Beta-2 Agonist Versus LAMA Alone in Moderate-to-severe Chronic Obstructive Pulmonary Disease:A Systematic Review and Meta-analysis of Randomized Trials", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "A Long-acting Muscarinic Antagonist (LAMA) Added to an Inhaled Corticosteroid and Long-acting Beta-2 Agonist Versus LAMA Alone in Moderate-to-severe Chronic Obstructive Pulmonary Disease:A Systematic Review and Meta-analysis of Randomized Trials", "subitem_title_language": "en"}]}, "item_type_id": "10002", "owner": "1", "path": ["57"], "permalink_uri": "https://showa.repo.nii.ac.jp/records/477", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-09-03"}, "publish_date": "2018-09-03", "publish_status": "0", "recid": "477", "relation": {}, "relation_version_is_last": true, "title": ["A Long-acting Muscarinic Antagonist (LAMA) Added to an Inhaled Corticosteroid and Long-acting Beta-2 Agonist Versus LAMA Alone in Moderate-to-severe Chronic Obstructive Pulmonary Disease:A Systematic Review and Meta-analysis of Randomized Trials"], "weko_shared_id": 1}
A Long-acting Muscarinic Antagonist (LAMA) Added to an Inhaled Corticosteroid and Long-acting Beta-2 Agonist Versus LAMA Alone in Moderate-to-severe Chronic Obstructive Pulmonary Disease:A Systematic Review and Meta-analysis of Randomized Trials
https://showa.repo.nii.ac.jp/records/477
https://showa.repo.nii.ac.jp/records/4772b118347-2d9a-4892-a2d3-f716963ede4f
名前 / ファイル | ライセンス | アクション |
---|---|---|
S30_1.pdf (517.7 kB)
|
|
Item type | 学内発行雑誌 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-09-03 | |||||
タイトル | ||||||
タイトル | A Long-acting Muscarinic Antagonist (LAMA) Added to an Inhaled Corticosteroid and Long-acting Beta-2 Agonist Versus LAMA Alone in Moderate-to-severe Chronic Obstructive Pulmonary Disease:A Systematic Review and Meta-analysis of Randomized Trials | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ | departmental bulletin paper | |||||
著者 |
ANDO, Koichi
× ANDO, Koichi× TANAKA, Akihiko× KUSUMOTO, Sojiro× YAMAOKA, Toshimitsu× OHMORI, Tohru× OHNISHI, Tsukasa× INOUE, Shin× SAGARA, Hironori |
|||||
書誌情報 |
The Showa University journal of medical sciences 巻 30, 号 1, p. 1-9, 発行日 2018-03 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | We assessed the overall efficacy and safety of a long-acting muscarinic antagonist (LAMA) added to an inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) as a combination therapy (LAMA+ICS/LABA) versus LAMA monotherapy in patients with chronic obstructive pulmonary disease (COPD). The overall efficacy and safety of LAMA+ICS/LABA versus LAMA in patients with COPD were assessed by a meta-analysis of randomized controlled trials (RCTs). We identified LAMA+ICS/LABA RCTs by searching PubMed, Scopus, and the Cochrane Library database. Primary efficacy outcomes were changes in forced expiratory volume in 1 second (FEV1.0) from baseline. Incidences of all adverse events (AAEs) were the primary safety outcomes. Pooled estimates are presented as mean differences (MDs) or risk ratios (RRs) with 95% confidence intervals (CIs). Analyses included intention-to-treat cases. Three LAMA+ICS/LABA RCTs met the criteria for inclusion in this study. The MD, RRs, and their 95% CIs regarding changes in FEV1.0 for LAMA+ICS/LABA compared with those of LAMA were 0.08 (0.04 to 0.13); RRs and 95% CIs for AAEs of LAMA+ICS/LABA compared with those of LAMA were 1.03 (0.82 to 1.29). Conclusions: Pulmonary function was significantly improved in the LAMA+ICS/LABA group with no significant increase in AAE risk. These results provide important analysis regarding the overall efficacy and safety of LAMA+ICS/LABA in patients with COPD. | |||||
DOI | ||||||
関連識別子 | 10.15369/sujms.30.1 | |||||
出版者 | ||||||
出版者 | Showa University Society | |||||
ISSN | ||||||
収録物識別子 | 0915-6380 | |||||
著者版フラグ | ||||||
出版タイプ | VoR |